1vpo
From Proteopedia
| Line 1: | Line 1: | ||
[[Image:1vpo.gif|left|200px]] | [[Image:1vpo.gif|left|200px]] | ||
| - | + | <!-- | |
| - | + | The line below this paragraph, containing "STRUCTURE_1vpo", creates the "Structure Box" on the page. | |
| - | + | You may change the PDB parameter (which sets the PDB file loaded into the applet) | |
| - | + | or the SCENE parameter (which sets the initial scene displayed when the page is loaded), | |
| - | | | + | or leave the SCENE parameter empty for the default display. |
| - | | | + | --> |
| - | + | {{STRUCTURE_1vpo| PDB=1vpo | SCENE= }} | |
| - | + | ||
| - | + | ||
| - | }} | + | |
'''Crystal Structure Analysis of the Anti-testosterone Fab in Complex with Testosterone''' | '''Crystal Structure Analysis of the Anti-testosterone Fab in Complex with Testosterone''' | ||
| Line 19: | Line 16: | ||
==About this Structure== | ==About this Structure== | ||
| - | + | This structure supersedes the now removed PDB entry [http://oca.weizmann.ac.il/oca-bin/send-pdb?obs=1&id=1l7s 1l7s]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1VPO OCA]. | |
==Reference== | ==Reference== | ||
Crystal structure of an in vitro affinity- and specificity-matured anti-testosterone Fab in complex with testosterone. Improved affinity results from small structural changes within the variable domains., Valjakka J, Hemminki A, Niemi S, Soderlund H, Takkinen K, Rouvinen J, J Biol Chem. 2002 Nov 15;277(46):44021-7. Epub 2002 Aug 23. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/12196551 12196551] | Crystal structure of an in vitro affinity- and specificity-matured anti-testosterone Fab in complex with testosterone. Improved affinity results from small structural changes within the variable domains., Valjakka J, Hemminki A, Niemi S, Soderlund H, Takkinen K, Rouvinen J, J Biol Chem. 2002 Nov 15;277(46):44021-7. Epub 2002 Aug 23. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/12196551 12196551] | ||
| - | [[Category: Mus musculus]] | ||
| - | [[Category: Protein complex]] | ||
[[Category: Hemminki, A.]] | [[Category: Hemminki, A.]] | ||
[[Category: Niemi, S.]] | [[Category: Niemi, S.]] | ||
| Line 31: | Line 26: | ||
[[Category: Takkinen, K.]] | [[Category: Takkinen, K.]] | ||
[[Category: Valjakka, J M.]] | [[Category: Valjakka, J M.]] | ||
| - | [[Category: | + | [[Category: Anti-steroid]] |
| - | [[Category: | + | [[Category: Fab fragment]] |
| - | [[Category: | + | [[Category: Testosterone complex]] |
| - | + | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May 3 12:46:06 2008'' | |
| - | ''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | + | |
Revision as of 09:46, 3 May 2008
Crystal Structure Analysis of the Anti-testosterone Fab in Complex with Testosterone
Overview
A highly selective, high affinity recombinant anti-testosterone Fab fragment has been generated by stepwise optimization of the complementarity-determining regions (CDRs) by random mutagenesis and phage display selection of a monoclonal antibody (3-C(4)F(5)). The best mutant (77 Fab) was obtained by evaluating the additivity effects of different independently selected CDR mutations. The 77 Fab contains 20 mutations and has about 40-fold increased affinity (K(d) = 3 x 10(-10) m) when compared with the wild-type (3-C(4)F(5)) Fab. To obtain structural insight into factors, which are needed to improve binding properties, we have determined the crystal structures of the mutant 77 Fab fragment with (2.15 A) and without testosterone (2.10 A) and compared these with previously determined wild-type structures. The overall testosterone binding of the 77 Fab is similar to that of the wild-type. The improved affinity and specificity of the 77 Fab fragment are due to more comprehensive packing of the testosterone with the protein, which is the result of small structural changes within the variable domains. Only one important binding site residue Glu-95 of the heavy chain CDR3 is mutated to alanine in the 77 Fab fragment. This mutation, originally selected from the phage library based on improved specificity, provides more free space for the testosterone D-ring. The light chain CDR1 of 77 Fab containing eight mutations has the most significant effect on the improved affinity, although it has no direct contact with the testosterone. The mutations of CDR-L1 cause a rearrangement in its conformation, leading to an overall fine reshaping of the binding site.
About this Structure
This structure supersedes the now removed PDB entry 1l7s. Full crystallographic information is available from OCA.
Reference
Crystal structure of an in vitro affinity- and specificity-matured anti-testosterone Fab in complex with testosterone. Improved affinity results from small structural changes within the variable domains., Valjakka J, Hemminki A, Niemi S, Soderlund H, Takkinen K, Rouvinen J, J Biol Chem. 2002 Nov 15;277(46):44021-7. Epub 2002 Aug 23. PMID:12196551 Page seeded by OCA on Sat May 3 12:46:06 2008
